Hairong Wang

Suzhou, 215025, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

NeuroD1-USP1-MYCN axis drives tumor progression in neuroblastoma.

NeuroD1-USP1-MYCN axis drives tumor progression in neuroblastoma.

Journal: Journal of translational medicine
Published: October 07, 2025

Core transcriptional regulatory circuit-regulated IGF2BP3 stabilizes E2F2 mRNA via m6A modification in neuroblastoma.

Core transcriptional regulatory circuit-regulated IGF2BP3 stabilizes E2F2 mRNA via m6A modification in neuroblastoma.

Journal: Carcinogenesis
Published: December 31, 2024

Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation.

Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation.

Journal: Neuro-oncology
Published: June 12, 2024

MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.

MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.

Journal: BMC cancer
Published: December 10, 2023

CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma.

CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma.

Journal: Cancer letters
Published: September 14, 2023

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines.

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines.

Journal: Chemical engineering journal (Lausanne, Switzerland : 1996)
Published: September 01, 2022

Super-enhancer-associated INSM2 regulates lipid metabolism by modulating mTOR signaling pathway in neuroblastoma.

Super-enhancer-associated INSM2 regulates lipid metabolism by modulating mTOR signaling pathway in neuroblastoma.

Journal: Cell & bioscience
Published: April 26, 2022

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.

Journal: Frontiers in oncology
Published: June 20, 2020
Showing 1-8 of 8

Last Updated: 09/26/2026